Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plague vaccine F1 + rV
- Development stage
- Phase 2
- Lead developer
- Jiangsu Provincial Center for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
A recombinant subunit vaccine designed to protect against plague caused by *Yersinia pestis*. It consists of two primary antigens: the natural Fraction 1 (F1) capsular protein and a recombinant version of the V (LcrV) antigen. These antigens are critical for the virulence of *Y. pestis* and are known to provide synergistic protection against both bubonic and pneumonic plague. The vaccine is being developed by the Jiangsu Provincial Center for Disease Control and Prevention and has been evaluated in Phase 2 clinical trials using various immunization regimens (e.g., 0-1-6 and 0-2-6 months). The formulation typically includes an adjuvant to enhance immunogenicity.
- Other names
- plague subunit vaccine (F1+rV)subunit vaccine of plague vaccine (F1+ rV)
02
Targets
F1 antigen (F1 capsular antigen)LcrV (V antigen)
Beyond the preview
Go deeper on plague vaccine F1 + rV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plague vaccine F1 + rV.